A pooled analysis of patients with established ASCVD showed a 10-year risk of recurrent ASCVD events of 20% and a lifetime risk of 54%. Theoretically, optimization of both lifestyle and medications could reduce both risks and add 7.3 event-free years.
ACC.23 “Lowering LDL-c by any means reduces CV events […], but any drug on its own is not going to be enough for high risk patients. We've got to use combination therapies and it’s great to have all these different options, which we can now combine in our patients”, says Prof. Ray.
ACC.23 Prof. Libby shares his view on the clinical impact of the results of the CLEAR Outcomes trial which investigated the effect of bempedoic acid on CV outcomes.
ACC.23 "Early treatment-related eGFR decline should not stall uptitration or impede continuation of ARNI", says Safia Chatur. She lists the findings of an analysis of PARADIGM-HF and PARAGON-HF in patients with HF.
ACC.23 In a multisite-RCT study was examined whether an intervention including individualized reminders sent to primary care clinicians improved use of high-intensity statin in patients with ASCVD.
ACC.23 In the COORDINATE-Diabetes trial was investigated whether a multifaceted intervention can improve prescription of 3 groups of evidence-based therapies in patients with T2DM and ASCVD.
ACC.23 Among men aged 45 to 70 years without CV risk factors, lifelong endurance athletes have a higher coronary plaque burden compared to participants who exercise up to 3 hours per week.
ACC.23 Injectable treatments may have poor adoption due to access barriers and the need for repeat injections. An oral PCSK9 inhibitor, MK-0616, was developed and tested in a phase 2b trial.
ACC.23 UK Biobank participants who followed a low-carbohydrate high-fat diet had higher LDL-c and apoB levels and an increased risk of incident MACE compared with those on a standard diet.
ACC.23 An EHR-embedded and selective alert delivered during the clinical encounter increased the likelihood of prescribing MRA by 2.5x in MRA-eligible HFrEF patients in an outpatient cardiology setting.
ACC.23 The CLEAR Outcomes study showed that among statin-intolerant primary and secondary prevention patients, bempedoic acid reduced the risk of the primary composite endpoint of nonfatal MI, nonfatal stroke, coronary revascularization or CV death.
ACC.23 Eugene Yang discusses the results of the CLEAR Outcomes trial and talks about the strengths and limitations of the study.